Keay Nakae
Stock Analyst at Chardan Capital
(4.15)
# 401
Out of 5,149 analysts
238
Total ratings
39.61%
Success rate
19.47%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Buy | $38 | $14.59 | +160.45% | 15 | Mar 3, 2026 | |
| ALUR Allurion Technologies | Upgrades: Buy | $2.5 → $3 | $0.70 | +328.57% | 8 | Feb 24, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $475 → $425 | $320.00 | +32.81% | 15 | Feb 13, 2026 | |
| IBIO iBio, Inc. | Maintains: Buy | $5 | $2.66 | +87.97% | 6 | Feb 12, 2026 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $53.85 | +85.70% | 7 | Jan 29, 2026 | |
| KRRO Korro Bio | Upgrades: Buy | $7 → $15 | $10.84 | +38.38% | 5 | Jan 29, 2026 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $4.73 | +195.98% | 23 | Jan 8, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 → $80 | $64.10 | +24.80% | 23 | Jan 7, 2026 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Buy | $2 | $0.24 | +748.54% | 1 | Jan 5, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $24 → $35 | $33.64 | +4.04% | 1 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $30 | $20.60 | +45.63% | 1 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 | $3.85 | +211.69% | 19 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $4.55 | +9.89% | 14 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $4.49 | +345.93% | 13 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $1.55 | +158.06% | 16 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $5.32 | +557.89% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $9.40 | -36.17% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $2.62 | +129.01% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.52 | +1,427.01% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $14.67 | -59.10% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $4.60 | +8,160.87% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $8.83 | +522.88% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $3.54 | +182.49% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $31.81 | +175.07% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.89 | +587.83% | 3 | Feb 9, 2021 |
Dyne Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $38
Current: $14.59
Upside: +160.45%
Allurion Technologies
Feb 24, 2026
Upgrades: Buy
Price Target: $2.5 → $3
Current: $0.70
Upside: +328.57%
Alnylam Pharmaceuticals
Feb 13, 2026
Maintains: Buy
Price Target: $475 → $425
Current: $320.00
Upside: +32.81%
iBio, Inc.
Feb 12, 2026
Maintains: Buy
Price Target: $5
Current: $2.66
Upside: +87.97%
Monopar Therapeutics
Jan 29, 2026
Maintains: Buy
Price Target: $100
Current: $53.85
Upside: +85.70%
Korro Bio
Jan 29, 2026
Upgrades: Buy
Price Target: $7 → $15
Current: $10.84
Upside: +38.38%
Coya Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $14
Current: $4.73
Upside: +195.98%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Buy
Price Target: $60 → $80
Current: $64.10
Upside: +24.80%
Reviva Pharmaceuticals Holdings
Jan 5, 2026
Maintains: Buy
Price Target: $2
Current: $0.24
Upside: +748.54%
Stoke Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $24 → $35
Current: $33.64
Upside: +4.04%
Jan 5, 2026
Maintains: Buy
Price Target: $15 → $30
Current: $20.60
Upside: +45.63%
Dec 18, 2025
Maintains: Buy
Price Target: $12
Current: $3.85
Upside: +211.69%
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.55
Upside: +9.89%
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $4.49
Upside: +345.93%
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $1.55
Upside: +158.06%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $5.32
Upside: +557.89%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $9.40
Upside: -36.17%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $2.62
Upside: +129.01%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.52
Upside: +1,427.01%
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $14.67
Upside: -59.10%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $4.60
Upside: +8,160.87%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $8.83
Upside: +522.88%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $3.54
Upside: +182.49%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $31.81
Upside: +175.07%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.89
Upside: +587.83%